ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026
Clinical application of metagenomic next-generation sequencing (mNGS) in children with suspected bloodstream infection.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Empowering One Health with metagenomics.One health outlook · 2026Review
- Clinical application value of metagenomic next-generation sequencing in children with fever of unknown origin.Frontiers in pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccurate and comprehensive pathogen diagnosis methods are urgently required for the diagnosis of bloodstream infection (BSI).This study retrospectively evaluated the clinical application of metagenomic next-generation sequencing (mNGS) in children with suspected BSI.
methodsBetween July 8, 2021 to December 31, 2022, mNGS tests and conventional methods tests (CMTs) were performed simulataneously on samples from children with suspected BSI. The diagnostic performance of mNGS was assessed in comparison CMTs .
resultsA total of 191 patients with suspected BSI were included in the final analysis after excluding 9 patients due to lost to follow-up or duplicated entries. The mNGS yielded positive results in 111 cases, with a positive rate of 58.1% (111/191), significantly higher than that of CMTs (13.1%, 25/191) (P < 0.05). Using CMTs as standard, the sensitivity, specificity, positive predictive value and negative predictive value for mNGS and CMTs were 73.8% vs. 25.0%, 54.2% vs. 96.3%, 55.9% vs. 84.0%, and 72.5% vs. 62.0%, respectively. Among 111 mNGS-positive cases, 46 cases (41.4%) showed ploymicrobial infections, with Torque teno virus, human betaherpesvirus 5, and human gammaherpesvirus 4 being most frequently identified pathogens. Of them, 62 cases (55.9%) were clinically diagnosed as BSI regarded as true positive results, while 49 cases (44.1%) positive for pathogens were diagnosed as non-BSI. The diagnostic time of mNGS was significantly shorter than that of CMTs (30.6 ± 7.7 h vs. 70.5 ± 11.6 h, P < 0.05). It is worth noting that mNGS results guided adjustments to antimicrobial therapy in 50.8% (97/191) patients, including escalation in 74 cases and de-escalation in 23 cases.
conclusionsThe mNGS significantly improves the detection rate for the pathogens in children with suspected BSI, especially for viruses, which serve as a complement to CMTs.
Indexed as
Identifiers
41037216What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.